



## AESCAP VENTURE INVESTS € 4 M IN TO-BBB

Amsterdam, July 6 2007

Aescap Venture invests € 4 million in the Dutch biotech company to-BBB. to-BBB's proprietary technology brings drugs to the brain that normally can not enter the brain due to the neuroprotective blood-brain barrier.

The company's lead product is fighting lethal viral infections of the brain using an existing broad-spectrum antiviral drug. The company's technology also targets neurodegenerative disorders like Alzheimer's disease, Stroke, Lysosomal Storage diseases and brain tumors.

Dr. Pieter Gaillard, CEO of to-BBB: "I am very pleased that we have closed this financing round with such an experienced international venture capital investor like Aescap. Aescap not only puts money on the table, but also the essential expertise to help us build and grow to-BBB into a large biomedical company."

to-BBB is a spin-off from Leiden University. Patrick Krol, partner at Aescap Venture, will chair to-BBB's Supervisory Board.

### Contacts:

Aescap Venture Management BV  
Patrick Krol  
Strawinskylaan 629  
World Trade Center B-Toren  
Amsterdam  
T: +31(0)20 570 2940  
F: +31(0)20 673 7846  
E-mail: [pkrol@aescap.com](mailto:pkrol@aescap.com)  
[www.aescap.com](http://www.aescap.com)

to-BBB technologies BV  
Pieter Gaillard  
Einsteinweg 55  
2333 CC  
Leiden  
T: +31(0)71 527 6268  
F: +31(0)84 870 9728  
E-mail: [gaillard@toBBB.com](mailto:gaillard@toBBB.com)  
[www.toBBB.com](http://www.toBBB.com)

## **About Aescap Venture**

Aescap Venture is a venture capital firm focusing on the creation and growth of European biomedical companies. Through early and active involvement in the companies, Aescap Venture will achieve an accelerated development of its portfolio companies and their products.

Since its first close in July 2006, Aescap Venture has made investments in three high-potential biomedical companies. These typically reflect Aescap's 'Acceleration Philosophy'. All companies - Affectis AG, ActoGeniX NV and ProtAffin AG - develop new generation medication and are led by successful biomedical entrepreneurs. Aescap aims to build a well-balanced investment portfolio consisting of 12 to 15 companies and typically invests in companies active in the most promising segments in the biomedical industry.

The founders of Aescap are Michiel de Haan, the founder and CEO of Atlas Venture until 2000 and Dinko Valerio PhD, the founder and former CEO of Crucell, a Euronext / NASDAQ-listed biotechnology company. Additional Partners are Patrick Krol MBA, a successful entrepreneur and expert in Life Science marketing and business development and Kreske Nickelsen MSc/MBA, previous Director at 3i, with 10 years of experience in European Life Science venture capital.

If you are interested in any further information, please contact Dinko Valerio or Patrick Krol at our Amsterdam office at +31(0)20 570 2945 or +31(0)6 5349 4955, E-mail: [dvalerio@aescap.com](mailto:dvalerio@aescap.com)

## **About to-BBB**

to-BBB is a Dutch, Leiden-based, privately-owned biotech company that brings drugs to the brain that normally cannot enter the brain. The company develops central nervous system (CNS) drugs based on a proprietary CNS drug targeting platform, 2B-Trans™, for the treatment of neurodegenerative disorders like Alzheimer's Disease, Stroke, Lysosomal Storage Diseases and brain tumors. to-BBB's lead product is fighting lethal viral infections of the brain using a broad-spectrum antiviral drug.

The 2B-Trans™ technology is unique in that it delivers drugs to the brain by an intravenous administration using a well characterized transport system with a specific carrier protein that has an excellent proven safety profile in humans.

Dr. Pieter Gaillard is founder and CEO of to-BBB, as well as the inventor of the 2B-trans™ technology. Together with Alfred Nijkerk (from VenGen B.V., a company offering experienced start-up management in life sciences) and Dr. Bert de Boer (Head of the renowned Blood-Brain Barrier Research Group of the Leiden/Amsterdam Center for Drug Research (LACDR) from Leiden University), Pieter Gaillard created the company in 2003 and subsequently secured two private equity seed rounds and numerous academic and industry collaborations.